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ABSTRACT
ValloVax is a placental endothelium derived vaccine which induces tissue-
nonspecific antitumor immunity by blocking tumor angiogesis. To elucidate 
mechanisms of action, we showed that production of ValloVax, which involves treating 
placental endothelial cells with IFN-gamma, results in upregulation of HLA and 
costimulatory molecules. It was shown that in mixed lymphocyte reaction, ValloVax 
induces Type I cytokines and allo-proliferative responses. Plasma from ValloVax 
immunized mice was capable of killing in vitro tumor-like endothelium but not control 
endothelium. Using defined antigens associated with tumor endothelial cells, specific 
molecular entities were identified as being targeted by ValloVax induced antibodies. 
Binding of predominantly IgG antibodies to ValloVax cells was confirmed by flow 
cytometry. Further suggesting direct killing of tumor endothelial cells was expression 
of TUNEL positive cells, as well as, reduction in tumor oxygenation. Supporting a role 
for antibody mediated responses, cell depletion experiments suggested a predominant 
role of B cells in maintaining an intact anti-tumor endothelial response. Adoptive 
transfer experiments suggested that infusion of CD3+ T cells from immunized mice 
was sufficient to transfer tumor protection. Generation of memory T cells selective to 
tumor endothelial specific markers was observed. Functional confirmation of memory 
responses was observed in tumor rechallenge experiments. Furthermore, we observed 
that both PD-1 or CTLA-4 blockade augmented antitumor effects of ValloVax. These 
data suggest a T cell induced B cell mediated anti-tumor endothelial response and set 
the framework clinical trials through elucidation of mechanism of action.
INTRODUCTION
Numerous approaches have been developed in 
attempts to selectively block tumor angiogenesis or induce 
collapse of tumor-associated blood vessels. While initial 
attempts such as development of endogenous inhibitors such 
as angiostatin and endostatin have failed, immunological 
means such as passive antibodies to VEGF (Avastin) have 
had success in terms of regulatory clearance and marketing 
approval. Drawbacks of Avastin include cardiotoxicity, 
development of resistance, has well as relatively poor 
survival advantage. Conceptually a more appealing method 
of inducing angiogenesis blockade would involve active 
immunization against several tumor endothelial associated 
antigens in the form of a polyvalent vaccine.
One major question that arises during attempts to 
induce active immunity to tumor associated endothelial is 
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the “horror autotoxicus” potential of stimulating immunity 
towards non-malignant endothelium. We recently reviewed 
numerous works in which immunization to proliferating 
endothelial cells, whether syngeneic, allogeneic or 
xenogeneic results in selectivity of killing of tumors without 
damage to non-malignant tissues [1]. This is a fundamental 
point because numerous antigens found on tumor endothelial 
cells are also found on non-malignant cells, for example 
VEGFR is known to be associated with hematopoietic stem 
cell self-renewal. Despite this, as reviewed, immunization 
with VEGFR protein or plasmid does not result in ablation of 
hematopoietic stem cells, as would be expected. Accordingly 
multiple mechanisms must be at operation that discriminate 
tumor endothelial from cells expressing similar markers but 
are not under immunological attack and destruction as a 
result of the immunization. This is supported by clinical data 
in which immunization with HUVEC cells multiple times 
did not result in hematopoietic or other toxicities.
While numerous attempts have been made at 
immunizing tumor bearing mice to endothelial antigens, 
the mechanistic data behind development of immunity has 
not been elucidated. Wei et al, for example, demonstrated 
involvement of antibodies targeting alpha V beta III 
integrin in suppression of tumor angiogenesis following 
immunization of mice with xenogeneic HUVEC cells 
[2]. Other studies have implicated T cell responses [3–5]. 
Indeed, in some situations not only collaboration between 
T cells and B cells is required for successful antitumor 
immunity, but also epitope spreading is observed between 
initial immunity towards tumor endothelium, which 
is subsequently followed by immunity towards tumor 
antigens themselves. Thus there is a high degree of 
variability of biological mechanisms between different 
active immunotherapies which target the tumor vasculature.
ValloVax is a human placental endothelial cell 
derived product, which has demonstrated human safety in 
an initial pilot clinical trial [6], as well as being shown to 
effectively reduce tumor growth in lung cancer, melanoma, 
and breast cancer [7]. In contrast to other endothelium based 
vaccines, ValloVax has the unique properties of: a) Large 
donor supply. Since ValloVax is generated from placental 
endothelial cells, there exists a virtually unlimited supply 
of placentas, and additionally, each placenta is capable of 
generating a large number of doses; b) ValloVax is optimized 
for immunogenicity by pre-treatment with interferon 
gamma; and c) Placental endothelial is biologically naïve, 
thus allowing for a higher degree of plasticity. The enhanced 
plasticity allows for higher levels of surface marker 
manipulation subsequent to treatment with cytokines.
Initial experiments performed in this report sought 
to confirm whether interferon gamma treatment indeed 
increases immunogenicity of placental endothelial 
cells, which was assessed by quantification of Signal I 
molecules (HLA) and Signal II (CD40, CD80, and CD86). 
Subsequently function assessment was performed in terms 
of T cell allostimulatory activity as well as ability to elicit 
cytokines associated with tumor regression. The experiments 
subsequently assessed whether indeed selectivity of killing 
was occurring, specifically, whether in vitro generated tumor 
endothelium-like tissue was a target for antibodies generated 
in vivo from ValloVax immunized mice, and whether in vivo 
killing of endothelial cells was occurring. At a physiological 
level the assessment of tumor oxygenation was performed. 
From an immunological perspective, the dependence of 
ValloVax induced tumor regression on T cells or B cells was 
assessed through depletion and adoptive transfer studies. 
Furthermore, ability to synergize with clinically-used 
checkpoint inhibitors was performed. The current series of 
studies sought to establish a mechanistic basis for ValloVax 
efficacy, which will serve as the foundation for future 
clinical development. Based on previous immunological 
experiments describing mechanisms of allogeneic tumor 
vaccines, the following conceptual framework was used for 
designing the experiments (Figure 1)
RESULTS
Antitumor activity of ValloVax across 
histologically-distinct tumors
In line with the hypothesis that ValloVax induces 
immunity to tumor endothelium, studies were conducted 
to determine whether administration of the vaccine would 
induce antitumor responses across histological tumor types. 
Previously we demonstrated that ValloVax vaccination 
inhibits growth of lung cancer, melanoma, and breast cancer 
[7]. In this study we utilized the GL261 glioma model and 
demonstrated suppression of tumor growth (Figure 2A). 
Additionally, using the CT-26 colon cancer model we 
demonstrated regression of established tumor (Figure 2B). 
In this model, superior activity of ValloVax was observed as 
compared to inhibition of VEGFR2 inhibition, suggesting 
the possible potency of active immunization towards a 
plurality of tumor endothelium associated antigens as 
compared to passive antibody transfer against one tumor 
vasculature associated antigen. These data support the 
possibility that ValloVax acts either by immunizing against 
antigens shared by all tumors, or by targeting a process 
common to all tumors, such as tumor angiogenesis.
Interferon gamma pretreatment stimulates HLA 
and costimulatory molecule upregulation
Interferon gamma has previously demonstrated to 
induce upregulation of HLA I and HLA II on a variety 
of cell types [8–10]. In the creation of a cancer vaccine 
candidate the utility of allogeneic cells as immunogens has 
previously been reported in melanoma [11, 12], lung cancer 
[13, 14], renal cell cancer [15, 16], colon cancer [17, 18], 
and breast cancer [19–21]. It is known that correlations exist 
between HLA expression and immunogenicity of cancer cell 
vaccines [22]. Accordingly, while the rationale of pretreating 
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cells with interferon is to upregulate immunogenicity, the 
actual determination of HLA upregulation, as well as effects 
on immunogenicity have not been reported. In a previous 
publication, antitumor efficacy of ValloVax treated with 
interferon gamma was demonstrated superior to untreated 
ValloVax [7], furthermore, increased expression of HLA 
I and II was demonstrated in endothelial cells pretreated 
with interferon gamma [23], but not in placental derived 
endothelial cells similar to ValloVax. As shown in Table 1, 
increased expression of HLA I and HLA II was observed 
in endothelial cells derived from all donor samples 
after treatment with interferon gamma for 48 hours. 
Interestingly upregulation of costimulatory molecules CD40, 
CD80, and CD86 was also observed.
Interferon gamma pretreatment of placental 
endothelial cells elicits hyperactive proliferative 
response from responding alloreactive T cells
It is known that HLA molecules present on 
stimulator cell are triggers of alloreactive responder T 
cell proliferation in mixed lymphocyte reaction [24]. 
Additionally, costimulatory molecule expression on 
stimulator cells of the mixed lymphocyte reaction also 
are known to enhance alloreactive T cell proliferation [25, 
26]. As seen in Figure 3, significant increases in T cell 
proliferation were seen at all stimulator to responder ratios 
subsequent to 48 hour treatment of placental endothelial 
stimulator cells to responders.
Interferon gamma pretreatment of placental 
endothelial cells elicits Th1 cytokines from 
responding alloreactive T cells
It is known that in mixed lymphocyte reaction, 
suppression of CD40, CD80, and CD86 is associated 
with reduction of T cell activation [27], stimulation of 
T regulatory cells [28], and upregulation of IL-10 [29]. 
Accordingly, given the upregulation of costimulatory 
molecules associated with interferon gamma pretreatment 
of placental endothelial cells, we sought to determine 
whether increased Th1 cytokines were produced when 
Figure 1: Multiple steps in the ValloVax-induced immune response. Initial recognition of MHC expressed on the ValloVax cell 
induces antigen presentation via indirect recognition. Engulfment of apoptotic bodies released from the ValloVax cells in the process of 
phagocytosis. Cross presentation of ValloVax antigens, inducing an antigen-specific cellular and humoral immune response. The homologies 
between angiogenesis targets expressed on the ValloVax cell and tumor endothelium result in a cross reaction where the immune response 
spreads to induce killing of the tumor vasculature.
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interferon gamma pretreated placental endothelial 
cells were utilized as stimulators. Interferon gamma 
pretreatment endowed placental endothelial cells ability 
to elicit upregulation of interferon gamma and IL-12 from 
responding T cells, as well as reduce production of IL-10. 
Interestingly, no modulation of IL-4 was observed 
(Figure 4).
Selectivity of immune response induced by 
ValloVax is specific to tumor endothelium  
in vitro
Several reports exist from in vitro and in vivo studies, 
including clinical studies that immunity can be selectively 
induced against tumor endothelium (reviewed in [1]). 
In order to assess whether immunization with ValloVax 
can induce immunity towards tumor endothelium, an in 
vitro model of tumor endothelium was created. Previous 
studies have reported that culture of murine endothelial 
cells with a cocktail of TGF-beta, IL-10 and PGE-2 was 
sufficient to endow TEM-1 and Fas ligand expression on 
non-malignant endothelium [30]. In order to replicate 
a tumor endothelial environment we utilized several 
cocktails of conditioned media from tumor cell lines (LLC 
(lung cancer), B16 (melanoma), RM-1 (prostate cancer), 
GL-261 (glioma), 4T1 (breast cancer)), as well as tumor 
associated cytokines (PGE-2, TGF-beta, and IL-10). Bone 
marrow endothelial cells cultured with these cytokines and 
conditioned media were assessed for similarity to tumor 
endothelium by quantification of expression of Fas ligand, 
TEM-1, and ability to induce apoptosis in PHA activated 
splenocytes. Interestingly, the only combination to elicit 
reproducible upregulation of characteristics of tumor 
endothelial cells was 4T1 conditioned media combined 
with TGF-beta. Specific criteria for identifying whether 
the non-malignant endothelial cells actually resembled 
Figure 2: Efficacy of ValloVax across histologically distinct tumors. GL-261 A. or CT-26 B. tumor cells were inoculated at 
time of vaccination or 10 days prior to vaccination, respectively, at a concentration of 1.7 x 10(6) or 5 x 10(5) cells per mouse. For GL-
261 experiments, ValloVax was administered weekly, whereas for CT-26 experiments, vaccination was administered at day 10 post tumor 
inoculation and day 17. Tumor growth was assessed at the indicated timepoints.
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Figure 3: IFN-gamma pretreatment enhances proliferation of responding lymphocytes in mixed lymphocyte reaction 
(MLR). Placental endothelial cells were treated for 48 hours with dilution buffer (control) 50 or 100 IU interferon gamma and mitotically 
inactivated by irradiation. Cells were plated at the indicated stimulator:responder ratio in round bottom 96-well plates and cultured for 72 
hours with tritiated thymidine added at the last 8 hours of culture. Proliferation was quantified by counts per minute. (*p < 0.01 as compared 
to control).
Table 1: Upregulation of HLA and costimulatory molecules by IFN-gamma pretreatment
Flow Cytometric evaluation of markers upregulate by IFN-gamma treatment of EC
Placenta 
Number Treatment HLA 1 HLA 2 CD40 CD80 CD86
1 Control ND + + + ND
1 50 U ++ ++ +++ ++ +++
1 100 U +++ ++ +++ ++ +++
2 Control ND ND ND + ND
2 50 U ++ ++ +++ ++ +
2 100 U +++ +++ +++ ++ ++
3 Control ND ND ND + ND
3 50 U ++ ++ +++ ++ +
3 100 U +++ +++ +++ ++ ++
4 Control ND ND ND + ND
4 50 U +++ +++ +++ +++ +
4 100 U +++ +++ +++ +++ ++
5 Control ND ND ND + ND
5 50 U ++ +++ +++ ++ +
5 100 U +++ +++ +++ ++ ++
Placental endothelial cells were isolated from 5 different donors and treated for 48 hours with dilution buffer (control) 50 
or 100 IU interferon gamma. Flow cytometry was utilized to assess expression of HLA I, HLA II, as well as costimulatory 
molecules CD40, CD80, and CD86. Quantification was performed by mean fluorescent intensity. ND = Not Detectable 
compare to isotype control; + = >25% MFI compared to isotype control; ++ = > 50% MFI compared to isotype control; 
+++ = > 75% MFI compared to isotype control; Experiments were done in triplicate in 3 different flow cytometry runs.
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tumor endothelium included: a) Enhanced FasL expression 
(MFI >2000); b) Upregulated TEM-1 expression (MFI 
>2000); and c) 200% increased apoptosis of PHA and 
antiCD3 anti CD28 activated splenocytes compared to 
non-treated.
To assess whether sera from immunized mice 
displayed preferential cytotoxicity towards in vitro 
generated tumor endothelium, mice were immunized 
4 times with 500,000 cells of ValloVax, or control 
immunization with hen egg white lysozyme (HEL) at 10 
ug/mouse. Immunization occurred on days 0, 7, 14, and 21, 
with mice being sacrificed at day 30. Sera was collected 
from control unimmunized mice, ValloVax immunized 
mice, and control HEL immunized mice. As seen in 
Figure 5A, no toxicity of sera was detected against healthy 
endothelial cells, whereas toxicity was observed against 
tumor-like endothelial cells in Figure 5B. Interestingly, a 
dose-dependent toxicity was only observed with sera from 
immunized but not either of the control mice.
Humoral responses were assessed using an in house 
generated ELISA for antibody responses to VEGFR1, 
TEM1, CD105, ROBO, FGFR2 and EGF-R. Although 
varying degrees of antibody responses were seen, all 
animals demonstrated a significant induction of antibody 
generation as seen in Figure 6. We confirmed expression 
of these antigens on placental endothelial cells prior 
to treatment with interferon gamma (Figure 7), and 
subsequent to treatment (Figure 8). In order to identify 
whether antibodies generated in immunized mice actually 
bound to ValloVax cells, sera from immunized mice 
was collected at various timepoints post immunization 
and incubated with ValloVax cells. Characterization of 
antibody isotype binding was performed using anti-IgG 
and anti-IgM secondary antibodies. As seen in Figure 
9, significant binding of IgG was noted, and antibody 
generation was time-dependent.
In vivo killing of tumor endothelial cells
Although previous studies have demonstrated 
inhibition and regression of tumor growth, mechanisms 
of tumor regression were investigated. Animals implanted 
with LLC tumors were immunized and sections where 
made to assess apoptosis with TUNEL staining. As seen 
in Figure 10A, an increased number of apoptotic cells 
were seen within the tumor tissue. Morphologically, 
apoptotic cells appeared to line the area adjacent to the 
blood supply of the tumor. Furthermore, quantification 
of tumor endothelial cells by CD31 staining revealed a 
reduced number of endothelial cells in the tumors, which 
correlated with tumor growth in Figure 10B. In order to 
definitively elucidate whether inhibition of tumor growth 
was occurring as a result of reduced oxygen supply, 
oximetry studies were conducted. Figure 10C illustrates 
Figure 4: IFN-Gamma pretreated placental endothelial cells evoke Th1-Like response in MLR. Placental endothelial cells 
were treated for 48 hours with dilution buffer (control) 50 or 100 IU interferon gamma and mitotically inactivated by irradiation. Cells were 
plated at the indicated stimulator:responder ratio in round bottom 96-well plates and cultured for 48 hours, after which production of the 
indicated cytokines was assessed by ELISA (*p < 0.01 as compared to control; #p < 0.05 as compared to control)
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Figure 6: Antibody responses to tumor endothelial markers. Sera from ValloVax immunized mice was used as a source of 
antibodies for quantification using ELISA detecting binding to indicated protein. Results are from sera of 6 mice per group and performed 
in triplicate.
Figure 5: Selective killing of tumor endothelial cells by sera from ValloVax immunized mice. Sera was collected from C57/
BL6 mice that were either: unimmunized; immunized with HEL; or immunized with ValloVax. Sera was incubated with either healthy bone 
marrow derived endothelium A. or bone marrow derived tumor-like endothelium B. Viability was represented as percentage of absorbance 
with untreated cells. Six mice per group were utilized and in vitro culture was representative of triplicate experiments performed at least 3 
times (*p < 0.01 as compared to control).
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Figure 7: Expression of tumor endothelial markers on umbilical endothelial cells prior to interferon gamma treatment. 
Purified CD31 endothelial cells were stained with; A. anti-VEGFR2; B. TEM-1; C. Endoglin; D. ROBO; E. FGF-R2; and F. EGF-R. Cells 
were gated on FSC and SSC and analyzed for the respective markers.
Figure 8: Expression of tumor endothelial markers on umbilical endothelial cells subsequent to interferon gamma 
treatment. Purified CD31 endothelial cells were cultured for 48 hours in the presence of 100 IU/ml of interferon gamma and subsequently 
stained with; A. anti-VEGFR2; B. TEM-1; C. Endoglin; D. ROBO; E. FGF-R2; and F. EGF-R. Cells were gated on FSC and SSC and 
analyzed for the respective markers.
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Figure 10: ValloVax induces reduction of tumor endothelial cells and reduces oxygenation. Mice bearing LLC tumors were 
immunized with ValloVax and apoptosis was assessed by TUNEL staining A., Endothelial cell content was assessed by CD31 staining B., 
and tumor oxygen content was assessed by oximetry C. Values represent 12 mice per group (*p < 0.01 as compared to control).
Figure 9: Assessment of class switching. ValloVax cells where fixed with paraformaldehyde 0.5% and bound to 96 well ELISA plates. 
Plates where incubated with sera from immunized mice, and goat anti-mouse anti-IgG and goat anti-mouse IgM where used as secondary 
antibodies.
Oncotarget28604www.impactjournals.com/oncotarget
reduction in oxygen content of ValloVax treated tumor 
bearing mice as compared to control.
ValloVax mediated tumor regression requires 
B cells
Previous studies have demonstrated that antibodies 
may mediate anti-tumor endothelial responses mediated 
by immunization with endothelial cell antigens [31]. 
Accordingly, we assessed whether cytotoxicity to 
ValloVax cells in vitro was mediated by antibodies. To 
confirm whether effects were mediated by antibodies, T 
cells and B cells were depleted by antibody administration. 
As shown in Figure 11, tumor regression mediated by 
ValloVax was abrogated by B cell depletion but not T 
cell depletion, although a reduction of tumor inhibitory 
effects was observed in T cell depleted mice. These 
data suggest that there is some T cell contribution to the 
tumor inhibitory effect, which is in line with the classical 
immunological notion that B cells require T cell cytokine 
and costimulatory molecule support.
T cells are required for adoptive transfer of 
tumor endothelial immunity
Despite the need for antibodies in the induction 
of immune mediated tumor regression subsequent to 
ValloVax immunization, adoptive transfer experiments in 
3 tumor models (B16, LLC, and 4T1) showed that CD3+ 
T cell transfer was capable of transferring immunity to 
all three tumors(Figure 12a–12c). This indicates that there 
may be a downstream activation of antigen-specific B cells 
subsequent to the adoptive transfer.
Memory T cell responses to selected tumor 
endothelial antigens
In order to assess whether memory T cells were 
generated in response to ValloVax, and whether the recall 
proliferative response resided in the memory or the naïve 
compartment, lymph node and spleen cells were harvested 
and separated into CD44high cells, which represent 
memory compartment and CD44low cells which represent 
naïve T cells. As seen in Figure 13, with exception of 
CD105 restimulation, all recall responses where higher in 
the memory T cell compartment for the antigens tested, 
which were, ValloVax, VEGFR1, VEGR2, FGFR, CD105, 
CD51, CD61, and TEM 1. To conclusively demonstrate 
induction of immunological memory subsequent to 
adoptive transfer, mice were rechallenged with tumor cells 
after initial clearance of tumors, in all cases tumors did not 
reestablish (Figure 14).
Stimulation of established tumor regression 
by combination of ValloVax with checkpoint 
inhibitors
Recent clinical trials have established the potency 
of checkpoint inhibitors against CTLA4 and PD1L in 
Figure 11: ValloVax mediated tumor regression is dependent on intact B cell compartment. Mice where depleted of T 
cells or B cells by anti-CD3, and anti-CD20 depletion prior to and subsequent to LLC tumor administration. Mice were immunized with 
ValloVax and tumor regression was quantified. Numbers represent 12 mice per group (*p < 0.01 as compared to control).
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Figure 13: Memory T cell proliferation responses to tumor endothelial markers. T cells were extracted from ValloVax 
immunized mice and separated into memory and naïve phenotype. Proliferation in response to indicated antigen is provided in CPM. 
Results are from lymphatic tissue of 6 mice per group and performed in triplicate (*p < 0.01 as compared to control).
Figure 12: Adoptive transfer of immunity to ValloVax. Purified T cells were extracted from immunized non-tumor bearing mice 
and transferred to naive mice that were subsequently inoculated with the designated tumor (A. 4T1, B. LLC, C. B16). Tumor regression 
was quantified. Numbers represent 12 mice per group.
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treatment of clinical tumors. Unfortunately checkpoint 
inhibitors possess the problem of lack of specificity to 
tumor tissue, thus in some cases causing autoimmunity. 
We sought to examine whether checkpoint inhibitors may 
potentiate ValloVax activity as assessed in an LLC model 
of established tumors. As seen in Figure 15, blockade 
of either CTLA4 or PD1 was not sufficient to induce 
regression of established tumors, whereas a synergy of 
effect was observed when combined with ValloVax.
Figure 14: Adoptive transfer of immunity to naïve mice. Immunized cells were collected from ValloVax treated mice as described 
in Materials and Methods. Recipient mice received 2, 5, and 10 million cells intravenously at time of tumor inoculation. For tumor 
rechallenge experiments, immunized mice that were tumor free on day 45-50 where challenged with 250,000, 500,000 or 1,000,000 tumor 
cells. Tumor growth was quantified.
Figure 15: Enhancement of ValloVax activity by checkpoint inhibition. Mice were implanted with LLC tumors, which were 
allowed to establish prior to immunization with ValloVax together with anti-CTLA4 A. or Anti-PD1 B. Tumor regression was assessed and 
each number indicates 12 animals per group. (*Animals were euthanized because of excessive tumor growth. ** p < 0.01 as compared to 
control, # p < .05 as compared to control).
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DISCUSSION
ValloVax is a GMP manufactured tumor endothelial-
targeting immunotherapy candidate currently in clinical 
development by Batu Biologics for treatment of Non-
Small Cell Lung Cancer (Investigational New Drug 
Application #16296). Previous studies have demonstrated 
antitumor efficacy of ValloVax in mouse models of breast 
and lung cancer, as well as melanoma. Confirmation 
of efficacy of ValloVax in tumors originating from 
histologically diverse tissues, particularly colon cancer 
and glioma, was performed in the current report. The 
reproducibility of this “universal vaccine” nature of 
ValloVax prompted us to evaluate mechanisms of 
ValloVax immunological activity, in part to identify 
cellular biomarkers that could be utilized in upcoming 
clinical trials, as well as to possibly explore means of 
augmentation of therapeutic effects. Although when 
compared to other tumor inhibitory immune vaccines [32–
34], ValloVax appears more potent at reduction of tumor 
mass, translation of murine data to the clinical situation is 
usually characterized by loss of efficacy, and accordingly, 
we desired to possess possible means to augment efficacy 
during the clinical development of this candidate.
The concept behind generating ValloVax from 
placental endothelial cells was the involvement of these 
cells in not only creation of the vascular infrastructure 
supporting the maternal-fetal interphase, but also the 
unique immunological environment in the placenta, 
which resembles tumor vasculature from the perspective 
of both expressing FasL [35, 36], IL-10 [37, 38], TGF-
beta [39], and other immune modulatory enzymes such 
as indolamine 2,3 deoxygenase [40]. Although other 
reports of endothelial cell vaccination have demonstrated 
immunity in humans without use of adjuvant, as quantified 
by antibodies to inoculation preparation [41], we sought 
to optimize immunogenicity of our endothelial vaccine 
by pretreatment with interferon gamma. In the current 
study found that placental endothelial cell treatment 
with interferon gamma increased immunogenicity of 
placental endothelial cells in vitro. Additionally, in vitro 
studies using artificially generated tumor endothelial lead 
to the finding of selective killing, which appeared to by 
IgG mediated, implying isotype and immunoglobulin 
class switching. The possibility of in vivo generation 
of antibodies suggests the feasibility of further epitope 
identification, as well as peptide vaccination.
We have identified several proteins that are 
found on ValloVax to which antibody responses are 
generated. These proteins comprised have previously 
been demonstrated to be present on tumor endothelium 
and have been used as targets of tumor endothelium 
vaccination: VEGFR2 [42–45], TEM-1 [46–48], Endoglin 
[49, 50], ROBO [51], FGF-R2 [5, 52], and EGF-R [53, 
54]. The therapeutic induction of immune response toward 
the polyvalent mixture found in ValloVax suggests the 
possibility of synergy. Indeed, Miller et al noticed synergy 
between vaccination to EGF-R and VEGF-R2 at inhibiting 
tumor neovascularization [54]. Other have reported similar 
synergies in various animal models between different 
tumor endothelial specific antigens [55, 56]. In a previous 
publication we reported a pilot study of 3 solid tumor 
patients immunized with ValloVax. Antibody responses to 
VEGFR2, TEM-1, Endoglin, ROBO, FGF-R2 and EGF-R 
were observed. Most importantly, no elevations of toxicity 
associated enzymes where reported. This is of particular 
importance because of the theoretically possible concern of 
non-specific toxicity towards non-malignant endothelium 
or development of antigen-antibody complexes. Enzymes 
assessed included kidney enzymes, which were in normal 
ranges post immunization, which is reassuring, given that 
other immunotherapies which have off-target toxicity have 
been shown to elevate creatinine [57].
The concept of inducing immunity to a multi-valent 
or polyvalent immunization inoculum is superior from 
an immunological perspective to single antigen mediated 
vaccination from the perspective of tumor endothelial 
targeting given that recent evidence is suggesting not 
only tumor cells, but also tumor endothelium is capable 
of mutating. One study demonstrated that tumors with 
higher metastatic activity possess endothelial cells with 
higher mutating activity [58]. In some studies horizontal 
transfer of genetic material to endothelial cells has been 
demonstrated, thus causing variability of gene expression 
in the tumor vasculature [59].
In vivo studies demonstrated selective killing of 
tumor endothelial cells, through what appears to be 
apoptosis as demonstrated by TUNEL staining. Given that 
other forms of immunologically mediated cell death exist, 
such as autophagy [60, 61], the question is still open as to 
how such massive levels of tumor cell death are occurring 
although the TUNEL staining revealed relatively little 
death. One possibility is that the selective killing of 
endothelial cells results in regression of tumor through 
oxygen starvation, a possibility supported by our studies 
in which physiological levels of oxygen were severely 
reduced in tumor bearing mice.
We found that antibodies elicited to ValloVax 
cross reacted with major well known tumor endothelial 
cell antigens, thus demonstrating conclusively that 
potency and multivalent nature of the immune response 
generated. Supporting the concept of class switching 
during antibody development are the findings that 
memory T cells were obtained. Studies are underway 
to identify whether epitopes of the memory T cells are 
similar amino acid sequences to the B cell epitopes. The 
possibility remains that by linking T and B cell peptides 
together a synthetic vaccine can be generated that lacks 
the need for placental isolation and cell culture. One 
interesting observation was the transference of tumor 
immunity by the T cell compartment. This possibility 
indicates that tumor endothelial antigens are released at 
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a basal rate from the tumor mass, which synergize with 
the adoptively transferred T cells. This suggests that 
processes already exist for immunological recognition 
of tumor endothelium, however T cell support is needed. 
Indeed other studies have shown the critical importance 
of T cells in supporting existing humoral tumor immune 
responses [62, 63]. Further support for immunological 
memory is the demonstration that mice which were 
rechallenged with tumor cells failed to develop tumors, 
even at concentrations of tumors as high as 10 million 
cells, which was observed in LLC, B16 and 4T1 systems.
Perhaps most striking were the tumor regression 
studies in which established tumors underwent 
considerable shrinkage subsequent to treatment with 
combination of checkpoint inhibitors and ValloVax. These 
data highly suggest the need to enter clinical trials with 
ValloVax alone, as well as in combination with classical 
checkpoint inhibitors. The possibility of enhancing 
specificity of checkpoint inhibitors while concurrently 
targeting the immune response to destroy tumor 
endothelium provides for enticing therapeutic possibilities. 
Another developmental possibility would be combination 
of ValloVax with CAR-T cell based approaches in order 
to augment efficacy in the treatment of solid tumors. 
The rationale would be that ValloVax induced anti-
tumor endothelial responses would allow for enhanced 
intratumoral penetration of the CAR-T cells.
In conclusion, the current paper provides a 
mechanistic basis for utilization of ValloVax as a “second 
generation” Avastin in that an ongoing T cell response 
directed against proliferating tumor endothelium will lack 
the need for continued immunization, as well as possess 
ability to generate immunological memory and diversity, 
which should provide a significant therapeutic advantage 
to the current antiangiogenic treatments that are on the 
market now.
MATERIALS AND METHODS
Animals and cells
Female C57BL/6 and BALB/c mice aged 8–12 weeks 
were purchased from The Jackson Laboratory. Animals were 
housed under conventional conditions at the Animal Care 
Facility, University of Western Ontario, and were cared for in 
accordance with the guidelines established by the Canadian 
Council on Animal Care. A murine melanoma cell line 
established from a C57BL/6 mouse and designated B16F10 
was obtained from the American Type Culture Collection 
(ATCC) and was maintained in RPMI 1640 medium 
(Sigma-Aldrich) with 10% FBS, l-glutamine, penicillin, and 
streptomycin at 37°C in 5% CO2. The murine mammary 
carcinoma 4 T1 cells (ATCC) were grown DMEM medium 
(Sigma-Aldrich) with 10% FBS, l-glutamine, penicillin, 
and streptomycin (complete DMEM) at 37°C in 5% CO2. 
Lewis Lung Carcinoma (LLC) is a murine lung carcinoma 
originating from C57/BL6 mice. The cells were maintained 
in RPMI 1640 supplemented with 10% fetal bovine serum, 
2 mM glutamine (Gibco-BRL, Life Technologies, Inc.). The 
cell line was cultured at 37°C in a 5% incubator. GL261 cells 
murine glioblastoma cells (H-2b haplotype) were obtained 
from ATCC and cultured in complete DMEM media. Cells 
were administered into C57/BL6 mice heterotopically into 
the subcutaneous tissue of the mouse flank at a concentration 
of 1.7 x 10(6) per inoculation. CT-26 murine colorectal 
cancer cells (ATCC) where grown in DMEM media and 
administered similarly as GL261 cells, with exception that 
inoculation was performed in BALB/c mice.
Mixed lymphocyte reaction
Stimulator cells where placental endothelial cells 
that were treated for 48 hours with dilution buffer (control) 
50 or 100 IU interferon gamma and mitotically inactivated 
by irradiation at 10 Gy. Cells were plated at the indicated 
stimulator:responder ratio, with 100,000 stimulators in 
round bottom 96-well plates and cultured for 72 hours 
with 1uC of tritiated thymidine added at the last 8 hours of 
culture. Proliferation was quantified by counts per minute.
For cytokine assessments, Quantikine ELISA kits (R 
& D Systems, Mannasses VA) were utilized. Conditioned 
media from MLR at 48 hours was used to assess cytokine 
production by responding cells.
GMP preparation of vaccine
ValloVax was produced under Good Manufacturing 
Practices (GMP) at iBiologics. Full term human placentas 
were collected from delivery room under informed 
consent. Fetal membranes were manually peeled back and 
the villous tissue is isolated from the placental structure. 
Villous tissue was subsequently washed with cold saline to 
remove blood and scissors used to mechanically digest the 
tissue. Lots of 25 grams of minced tissue were incubated 
with approximately 50 ml of HBSS with proprietary 
enzymatic digestion mixture. The supernatant collected 
from all three incubations was then pooled and is poured 
through approximately four layers of sterile gauze and 
through one layer of 70 micrometer polyester mesh. 
The suspension was subsequently mixed with 10 ml of 
90% Percoll to give a final density of 1.027 g/ml and 
centrifuged at 550 g for 10 minutes with the centrifuge 
brake off. The pellet was then washed in HBSS and cells 
incubated for 48 hours in complete DMEM media. After 
3–4 passages cells were incubating in media containing 
100 IU of IFN-gamma per ml. Subsequent to incubation 
cells were either used: a) unmanipulated; b) used as a 
lysate, with 10 freeze thaw cycles in liquid nitrogen, 
subsequent to which lysate was filtered through a 0.2 
micron filter; c) mitotically inactivated by irradiation at 
10 Gy; or d) inactivated by fixation in 0.5% formalin and 
subsequently washed.
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Immunization schedules and tumor assessment
For induction of tumor growth, 5 × 105 B16, LLC, or 
4 T1 cells, American Type Culture Collection (Manassas, 
VA) cells were injected subcutaneously into the hind 
limb flank. Four weekly vaccinations of 5 × 105 test cells 
were administered subcutaneously on the contralateral 
side to which tumors were administered. Vaccination was 
performed on the day of tumor inoculation and on days 7, 
14, and 21.
For GL261 studies, vaccination was performed 
on the day of tumor inoculation, followed by weekly 
administration. Vaccination dose was 1.7 x 10(6) cells per 
vaccination. For CT-26 studies, mice were immunized 10 
days prior to tumor inoculation, as well as on days 10 and 
17 subsequent to inoculation. Concentration of ValloVax 
cells was 5 x 10(5) cells per vaccination.
Tumor growth was assessed every 3 days by two 
measurements of perpendicular diameters by a caliper, and 
animals were sacrificed when tumors reached a size of 1 
cm in any direction. Tumor volume was calculated by the 
following formula: (the shortest diameter2 × the longest 
diameter)/2.
Adoptive transfer and tumor rechallenge
Donor mice syngeneic to recipient mice were 
immunized twice with ValloVax at days 0 and 7 at a 
concentration of 5 x 10(5) cells per injection. Mice were 
euthanized at day 14 by carbon dioxide asphyxiation 
followed by cervical dislocation. Lymph nodes where 
dissected mechanically and dissociated over a .45 sterile 
mesh in a solution of PBS with DNase 0.05 ug/ml. Cells 
were centrifuged twice in 5 ml of PBS and subsequently 
counted for viability. Recipient mice received 2, 5, and 10 
million cells intravenously at time of tumor inoculation. 
For tumor rechallenge experiments, immunized mice 
that were tumor free on day 45-50 where challenged with 
250,000, 500,000 or 1,000,000 tumor cells. Tumor growth 
was quantified.
Memory cell assessment
C57/BL6 mice were immunized with Vallovax on 
days 1, 7, 14, and 21 and sacrificed on day 30. T cells 
were purified from single-cell suspensions of pooled 
lymphoid tissues (spleens and cervical, axillary, and 
inguinal lymph nodes). Naıve cells obtained by negative 
selection on CD4 T cell columns (R and D Systems), 
using the manufacturer’s directions modified by adding 
anti-CD44 antibody to the antibodies supplied with the 
kit. Anti-CD44 antibodies selectively bind to CD44 hi 
memory activated cells and allow them to be retained in 
the column and removed from the suspension. Memory 
cells were purified by adding 5 mg/ml of sodium azide-
free anti-CD62L antibodies (PharMingen) to those 
supplied with the CD4 column kit. CD62L is expressed 
selectively on naıve cells, and this marker was used to 
remove the CD62L naïve cells from the suspension. 
BM derived DC where added at a concentration of 
100,000 cells per well from B6 mouse in 96 well plate, 
antigen (ValloVax lysate or protein) was added at 
concentrations of 0.1, 1, 10 ug. Furthermore memory 
(CD44+) or naïve cells (CD44-) T cells were placed 
at 100,000 cells per well. The mixture was incubated 
for 48 hours and proliferation was assessed by tritiated 
thymidine (1 microcurie/well) incorporation for 6 hours. 
Quantification of thymidine uptake was performed by 
measurement of counts per minute using scintillation 
counting (1205 Betaplate Liquid Scintillation Counter, 
WALLAC Inc., Gaithersburg, MD).
Generation of in vitro tumor endothelium
BM CD31 selected cells were grown in Lonza EC 
media, and treated with TGF-beta (100 ng/ml) with 25% 
4T1 supernatant. After culture for 48 hours, assessment 
of FasL and ability to induce apoptosis in PHA and anti-
CD3/CD28 activated T cells was performed and compared 
to control BM CD31 selected cells, grown in Lonza EC 
media without TGF or 4T1 supernatant. These “tumor-
like” EC where subsequently incubated for 48 hours with 
sera from immunized mice, 4 immunizations, sacrificed at 
day 30, used HEL immunization, same schedule as control. 
Assessed with ProMega Viability assay as percentage of 
control viability. Numbers are from 6 mice per group, in 
vitro done in triplicate x 3
Immunohistochemistry
4-μm paraffin sections were deparaffinized in xylol 
and rehydrated in graded alcohol series. Endogenous 
peroxidase was inhibited using 3% H2O2 in methanol. The 
sections were then washed in distilled water and heated 
in a microwave oven (in citrate buffer 10 mM, pH 6, for 
CD31, and EDTA 1 mM, pH 7.5, for factor VIII) 15 min 
for epitope retrieval. No pretreatment was needed for D2-
40. Slides were incubated first with normal horse serum 
(1/30 avidin 10%) for CD31 and with normal goat serum 
(10% avidin) for factor VIII and Fli-1 for 5 min and then 
in biotin for 10 min. Endogenous biotin was inhibited with 
a Vector Blocking kit (Vector Laboratories; Burlingame, 
CA). The slides were then incubated at 20C for 40 min 
with monoclonal antibodies for CD31, the slides were 
incubated overnight at 8C. The slides were incubated 
with anti-mouse/rabbit biotinylated bridging antibodies 
(dilution 1/200) for 30 min. Sections were then washed 
and incubated with standard avidin-biotin complex 
(ABC; DakoCytomation, Glostrup, Denmark) for 30 min. 
Antibody binding was revealed using H2O2 as a substrate 
and diaminobenzidine as chromogen. Counterstaining was 
performed with hematoxylin.
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Flow cytometry
Cells were suspended in phosphate buffered saline 
(PBS) and then incubated for 30 min at 4°C with the 
antibodies conjugated with FITC or PE against HLA 
I, HLA II, CD31, CD40, CD80, CD86, VEGFR-2, 
TEM-1, Endoglin, ROBO-4, FGFR-2, EGF-R and 
FasL. Flow cytometry analyses were performed using 
a FACSCalibur (BD Biosciences, San Jose, CA, USA). 
Acquired data were then analyzed by utilizing the Win-
MDI software.
ELISA for mouse immunizations and isotype 
analysis
Blood was extracted from the mice (~100 μl) 
by puncturing the radial venous with a 26G needle 
(Terumo Medical Corporation, Tokyo, Japan), and 
using heparinized micro-hematocrit tubes (Drummond 
Scientific Company, Broomall, PA, USA). The blood was 
centrifuged at 3,200 × g for 15 min to obtain the serum, 
which was stored at −20°C until analysis. For ELISA 
high-binding Nunc™ 96-well polystyrene plates (Thermo 
Fisher Scientific, Inc., Waltham, MA, USA), were coated 
overnight with 10 μg/ml of protein (VEGFR-1, TEM-1, 
CD105, ROBO-4, FGF-R2, EGF-R) at 4°C in carbonate/
bicarbonate buffer (0.1 M; pH 9.6; Merck, Kenilworth, 
NJ, USA). Titrations where performed in PBS (0.1 M; 
pH 7.4) containing 2% bovine serum albumin (BSA; 
Sigma-Aldrich, St Louis, MO, USA). The plates were 
incubated for 3 h at 37°C. Subsequently, polyclonal 
rabbit anti-mouse immunoglobulin (Ig)G antibody 
conjugated to peroxidase was diluted to 1:10,000 in PBS 
(0.1 M; pH 7.4) and 2% BSA, was added to the plates. 
The antigen-antibody reaction was detected by addition 
of o-phenylenediamine (EMD Millipore) and a H2O2 
substrate (EMD Millipore), which was dissolved in 
disodium phosphate (0.02 M, pH 5.0; EMD Millipore). 
The colorimetric reaction was read at 490 nm using a plate 
reader (Multiskan™ GO Microplate Spectrophotometer; 
Thermo Fisher Scientific, Inc.).
For assessment of antibody binding an isotype 
class switching, ValloVax cells where fixed with 
paraformaldehyde 0.5% and bound to 96 well ELISA 
plates. Plates where incubated with sera from immunized 
mice, and goat anti-mouse anti-IgG and goat anti-mouse 
IgM where used as secondary antibodies.
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